Plasma Fractionation Market Size, Share, By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others), Method (Centrifugation, Depth Filtration, Chromatography, and Others), Application (Neurology, Hematology, Oncology, Immunology, Pulmonology, and Others), End-User (Hospitals and Clinics, Clinical Research Laboratories, Research Institutions, and Others), and Region - Trends, Analysis, and Forecast till 2035

• CSL
• Grifols, S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Bio Products Laboratory Ltd.
• LFB
• Biotest AG
• Syntegon Technology GmbH
• ADMA Biologics
• Intas Pharmaceuticals Ltd.

Recent News:

• Permira, the global private equity firm, announced its collaboration with Kedrion’s existing shareholders (the Marcucci family and FSI) to jointly acquire and combine Kedrion and BPL, in January 2022. The combination created a global player for medicines derived from human blood plasma, leading to plasma fractionation, which helped in treating patients with rare and life threatening conditions
• The Vice President of Indonesia, encouraged the Indonesian Red Cross (PMI) and relevant parties to develop a local plasma fractionation program to reduce the importation of plasma-derived medicinal products, in August 2024. The vice president expressed hope that the innovation would ensure sustainable access to safer and more reliable blood and blood products in Indonesia.